Literature DB >> 15918110

The growth hormone hypothesis - 2005 revision.

J Frystyk1.   

Abstract

Growth hormone (GH) and insulin-like growth factor I (IGF-I) have been suggested to play a leading role in the development of diabetic retinopathy for more than three decades . At the time of writing, there is a substantial amount of experimental data supporting a role of GH and IGF-I in the development of diabetic retinopathy, whereas clinical trials have yielded variable results. However, both hormones, with IGF-I as the ringleader, remain under suspicion as pathogenic agents. This mini-review will discuss the current literature on the possible involvement of GH and IGF-I in the development of diabetic retinopathy. Hopefully, the reader will agree that although the indictment against GH and IGF-I has celebrated its 34th anniversary, it is still attractive from a scientific point of view.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15918110     DOI: 10.1055/s-2005-861362

Source DB:  PubMed          Journal:  Horm Metab Res        ISSN: 0018-5043            Impact factor:   2.936


  12 in total

1.  Monitoring of Diabetic Retinopathy in relation to Bariatric Surgery: a Prospective Observational Study.

Authors:  Troels Brynskov; Caroline Schmidt Laugesen; Annette Lykke Svenningsen; Andrea Karen Floyd; Torben Lykke Sørensen
Journal:  Obes Surg       Date:  2016-06       Impact factor: 4.129

2.  Selective inner retinal dysfunction in growth hormone transgenic mice.

Authors:  Brent T Martin; Edward O List; John J Kopchick; Yves Sauvé; Steve Harvey
Journal:  Growth Horm IGF Res       Date:  2011-06-25       Impact factor: 2.372

Review 3.  Novel targets against retinal angiogenesis in diabetic retinopathy.

Authors:  Shuang Wang; James K Park; Elia J Duh
Journal:  Curr Diab Rep       Date:  2012-08       Impact factor: 4.810

4.  The IGF-Axis and Diabetic Retinopathy Before and After Gastric Bypass Surgery.

Authors:  Troels Brynskov; Caroline Schmidt Laugesen; Andrea Karen Floyd; Jan Frystyk; Torben Lykke Sørensen
Journal:  Obes Surg       Date:  2017-02       Impact factor: 4.129

5.  IGFBP3 suppresses retinopathy through suppression of oxygen-induced vessel loss and promotion of vascular regrowth.

Authors:  Chatarina Lofqvist; Jing Chen; Kip M Connor; Alexandra C H Smith; Christopher M Aderman; Nan Liu; John E Pintar; Thomas Ludwig; Ann Hellstrom; Lois E H Smith
Journal:  Proc Natl Acad Sci U S A       Date:  2007-06-13       Impact factor: 11.205

6.  Increased intraocular insulin-like growth factor-I triggers blood-retinal barrier breakdown.

Authors:  Virginia Haurigot; Pilar Villacampa; Albert Ribera; Cristina Llombart; Assumpcio Bosch; Victor Nacher; David Ramos; Eduard Ayuso; José C Segovia; Juan A Bueren; Jesus Ruberte; Fatima Bosch
Journal:  J Biol Chem       Date:  2009-05-27       Impact factor: 5.157

Review 7.  Biodegradable intraocular therapies for retinal disorders: progress to date.

Authors:  Noriyuki Kuno; Shinobu Fujii
Journal:  Drugs Aging       Date:  2010-02-01       Impact factor: 3.923

Review 8.  Chronic limb-threatening ischemia could benefit from growth hormone therapy for wound healing and limb salvage.

Authors:  Diego Caicedo; Pablo Devesa; Víctor M Arce; Julia Requena; Jesús Devesa
Journal:  Ther Adv Cardiovasc Dis       Date:  2017-12-22

9.  Hydrogen improves glycemic control in type1 diabetic animal model by promoting glucose uptake into skeletal muscle.

Authors:  Haruka Amitani; Akihiro Asakawa; Kaichun Cheng; Marie Amitani; Kaori Kaimoto; Masako Nakano; Miharu Ushikai; Yingxiao Li; Minglun Tsai; Jiang-Bo Li; Mutsumi Terashi; Huhe Chaolu; Ryozo Kamimura; Akio Inui
Journal:  PLoS One       Date:  2013-01-10       Impact factor: 3.240

10.  Effects of human insulin and insulin aspart preparations on levels of IGF-I, IGFBPs and IGF bioactivity in patients with type 1 diabetes.

Authors:  Zhulin Ma; Jens Sandahl Christiansen; Torben Laursen; Chunsen Wu; Torsten Lauritzen; Tina Parkner; Jan Frystyk
Journal:  BMC Endocr Disord       Date:  2014-04-11       Impact factor: 2.763

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.